Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
IPO Year: 2021
Exchange: NASDAQ
Website: instilbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2025 | $11.00 → $52.00 | Hold → Buy | Jefferies |
| 1/7/2025 | $11.00 → $52.00 | Hold → Buy | Truist |
| 11/4/2024 | Mkt Perform | JMP Securities | |
| 4/12/2024 | $5.00 → $11.00 | Buy → Hold | Jefferies |
| 11/1/2022 | $16.00 → $6.00 | Buy → Hold | Truist |
| 11/1/2022 | Outperform → Market Perform | Cowen | |
| 8/13/2021 | $34.00 | Outperform | Robert W. Baird |
| 8/13/2021 | $34.00 | Outperform | Baird |
Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer dosed with ITIL-306, the first engineered TIL therapy using CoStAR Platform, with plans to share clinical data in 2023 Appointment of cell therapy pioneer Dr. Robert Hawkins as Head of Research and Development, and resignation of Chief Medical Officer, Dr. Zachary Roberts Company confirms cash runway into 2025 with anticipated sale-leaseback transaction of its Tarzana manufacturing facility DALLAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("
DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced the appointment of Tim Moore to the role of Chief Operating Officer. Tim Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations, including at Genentech, Kite and most recently PACT Pharma. From 2016 to 2019, Mr. Moore was Executive Vice President, Technical Operations at Kite Pharma, where he was responsible for technical operations and successfully launched Yescarta®, one of the fi
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
SC 13D/A - Instil Bio, Inc. (0001789769) (Subject)
SC 13G - Instil Bio, Inc. (0001789769) (Subject)
SC 13G - Instil Bio, Inc. (0001789769) (Subject)
SC 13G - Instil Bio, Inc. (0001789769) (Subject)
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
Jefferies upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously
Truist upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously
JMP Securities initiated coverage of Instil Bio with a rating of Mkt Perform
Jefferies downgraded Instil Bio from Buy to Hold and set a new price target of $11.00 from $5.00 previously
Truist downgraded Instil Bio from Buy to Hold and set a new price target of $6.00 from $16.00 previously
Cowen downgraded Instil Bio from Outperform to Market Perform
Robert W. Baird initiated coverage of Instil Bio with a rating of Outperform and set a new price target of $34.00
Baird initiated coverage of Instil Bio with a rating of Outperform and set a new price target of $34.00
Morgan Stanley reiterated coverage of Instil Bio with a rating of Equal-Weight and set a new price target of $23.00 from $24.00 previously
Jefferies initiated coverage of Instil Bio with a rating of Buy and set a new price target of $31.00
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025 Enrollment of 1L NSCLC patients in trial of AXN-2510/IMM2510 and chemotherapy by ImmuneOnco in China anticipated to begin in Q2 2025 with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS, March 04, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("I
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China ImmuneOnco announced initial clinical data from the 1L advanced NSCLC trial in China is expected as early as 2H 2025 Instil is targeting initiation of a potential first-line advanced NSCLC clinical trial of IMM2510/SYN-2510 combined with chemotherapy in 2H 2025, assuming necessary regulatory approvals DALLAS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL, "Instil")), today announced clinical progress of IMM2510/SYN-2510 in China by its collaborator, ImmuneOnco Biopharmaceutica
Licensed SYN-2510, a potential best-in-class PD-L1xVEGF bispecific antibody, for global ex-China development and commercialization Clinical data update for SYN-2510/IMM2510 in China from ImmuneOnco anticipated in 1H 2025 Initiation of Phase 1b/2 SYN-2510/IMM2510 + chemotherapy combination in first-line non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) anticipated in late 2024 and 1H 2025, respectively, by ImmuneOnco in China U.S. clinical study of SYN-2510/IMM2510 in NSCLC initiation targeted for 2H 2025 DALLAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a
Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC)Global registrational strategy in first-line triple-negative breast cancer (TNBC)Initiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line NSCLC anticipated in late 2024 in ChinaInitiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line TNBC anticipated in early 2025 in ChinaUS IND submission for SYN-2510 targeted in late 2024, starting with Phase 2 trial of SYN-2510 monotherapy in second-line NSCLC DALLAS and SHANGHAI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL, ", Instil", ))) and ImmuneOnco Biopharmaceuticals (Sh
In-licensed SYN-2510/IMM2510, a potentially best-in-class PD-L1xVEGF bispecific antibody, and SYN-27M/IMM27M, a next-generation ADCC-enhanced anti-CTLA-4 antibodyEntered into a 15-year lease for our cell therapy manufacturing facility to AstraZeneca Pharmaceuticals LP DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update. "We have expanded our pipeline with a pair of clinical-stage, potentially best-in-class therapeutics by in-licensing SYN-2510 and SYN-27M," said Bronson Crou
DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL, "Instil"))) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, "ImmuneOnco"), today announced a definitive agreement pursuant to which Instil is in-licensing ex-China development and commercial rights to ImmueOnco's proprietary PD-L1xVEGF bispecific antibody, IMM2510, as well as its next-generation anti-CTLA-4 antibody, IMM27M. IMM2510 is a novel, potentially best-in-class bispecific antibody consisting of an anti-PD-L1 antibody fused to a vascular endothelial growth factor (VEGF) receptor "trap" which binds VEGF. IMM2510 is differentiated from other PD(L)1xVEGF antibodies by its abili
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update. Recent Highlights: With successful completion of feasibility studies, preparations are underway with collaborator for a potential investigator-initiated trial (IIT) in non-small cell lung cancer with folate receptor α (FRα)-CoStAR TILExploring opportunities to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical needCash runway expected beyond 2026 First Quarter 2024 Financi
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update. Recent Highlights: Announced entering into a strategic collaboration to develop an autologous folate receptor α (FRα)-CoStAR enhanced TIL for a potential investigator-initiated trial (IIT) in non-small cell lung cancer in ChinaAnnounced a strategic update to the ITIL-306 program, including closure of Instil's UK manufacturing and cessation of ITIL-306 clinical trial activitiesExploring opportunities to in-li
DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced a strategic update. Instil has entered into an agreement with a collaborator that has a successful track record of manufacturing and dosing patients with cell therapies to conduct preclinical manufacturing feasibility studies in the ITIL-306 program. The feasibility studies have been initiated, and if the feasibility studies are successful, Instil's collaborator may open an investigator-initiated clinical trial (IIT)
DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on Thursday, December 7, 2023. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on December 8, 2023. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol
DEFR14A - Instil Bio, Inc. (0001789769) (Filer)
DEFA14A - Instil Bio, Inc. (0001789769) (Filer)
DEF 14A - Instil Bio, Inc. (0001789769) (Filer)
424B5 - Instil Bio, Inc. (0001789769) (Filer)
S-8 - Instil Bio, Inc. (0001789769) (Filer)
10-K - Instil Bio, Inc. (0001789769) (Filer)
8-K - Instil Bio, Inc. (0001789769) (Filer)
SCHEDULE 13G/A - Instil Bio, Inc. (0001789769) (Subject)
8-K - Instil Bio, Inc. (0001789769) (Filer)
8-K - Instil Bio, Inc. (0001789769) (Filer)